Management of adenocarcinoma of prostate with diethylstilbestrol diphosphate and cyclophosphamide.

Abstract

Eleven patients with terminal metastatic prostatic carcinoma were selected for a pilot study to evaluate how effective diethylstilbestrol diphosphate (Stilphostrol) and cylcophosphamide (Cytoxan) are in this disease. Six of 7 patients had a good response when treated with diethylstilbestrol diphosphate. The mean duration of response was 6.4 months. All 6 patients given cyclophosphamide had marked relief of pain and increased mobility. Of these, 3 died twelve, sixteen, and nineteen weeks, respectively, following initiation of therapy while still benefiting from pain relief. The mean duration of response was 14.8 weeks.

• Authors: G R Sinclair, A N Lupu, J B de Kernion
• Journal: Urology (Urology) Vol. 5 Issue 5 Pg. 665-8 (May 1975) ISSN: 0090-4295 [Print] United States
• PMID: 48303 (Publication Type: Journal Article)

Chemical References

• Diethylstilbestrol
• Cyclophosphamide

Topics

• Adenocarcinoma (drug therapy)
• Cyclophosphamide (therapeutic use)
• Diethylstilbestrol (therapeutic use)
• Humans
• Male
• Palliative Care
• Pilot Projects
• Prostatic Neoplasms (drug therapy)